Anavex Life Sciences (AVXL) Other financing activities (2012 - 2022)
Anavex Life Sciences recorded quarterly Other financing activities of $198.0 in Q3 2022, down 99.89% quarter-over-quarter from $185361.0 in Q2 2022, and down 98.87% year-over-year from $17539.0 in Q3 2021.
Anavex Life Sciences' Other financing activities history runs 6 years deep, the most recent figure standing at $198.0 for Q3 2022.
- In Q3 2022, Other financing activities fell 98.87% year-over-year to $198.0; the TTM figure through Sep 2022 stood at $707000.0 (down 87.26% YoY), while the FY2022 annual figure was $707000.0, down 87.26% from the prior year.
- Other financing activities came in at $198.0 for Q3 2022 at Anavex Life Sciences, down from $185361.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $4.4 million in Q2 2021 to a low of $198.0 in Q3 2022.
- A 4-year average of $521688.8 and a median of $146717.0 in 2021 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities soared 17848.28% in 2021 and plunged 98.87% in 2022, its largest moves.
- Anavex Life Sciences' Other financing activities stood at $50000.0 in 2018, then jumped by 426.92% to $263460.0 in 2020, then plunged by 44.31% to $146717.0 in 2021, then plunged by 99.87% to $198.0 in 2022.
- According to Business Quant data, Other financing activities over the past three periods registered $198.0, $185361.0, and $374724.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 198.00 |
| Sep 30, 2022 | 198.00 |
| Jun 30, 2022 | 185,361.00 |
| Jun 30, 2022 | 185,361.00 |
| Mar 31, 2022 | 374,724.00 |
| Mar 31, 2022 | 374,724.00 |
| Dec 31, 2021 | 146,717.00 |
| Dec 31, 2021 | 146,717.00 |
| Sep 30, 2021 | 17,539.00 |
| Sep 30, 2021 | 17,539.00 |
| Jun 30, 2021 | 4.40 Mn |
| Jun 30, 2021 | 4.40 Mn |
| Mar 31, 2021 | 871,237.00 |
| Mar 31, 2021 | 871,237.00 |
| Dec 31, 2020 | 263,460.00 |
| Dec 31, 2020 | 263,460.00 |
| Sep 30, 2020 | 379,256.00 |
| Sep 30, 2020 | 379,256.00 |
| Jun 30, 2020 | 24,508.00 |
| Jun 30, 2020 | 24,508.00 |
| Dec 31, 2018 | 50,000.00 |
| Dec 31, 2018 | 50,000.00 |
| Sep 30, 2018 | 51,133.00 |
| Sep 30, 2018 | 51,133.00 |
| Jun 30, 2018 | 19,057.00 |
| Jun 30, 2018 | 19,057.00 |
| Jun 30, 2014 | 53,872.00 |
| Jun 30, 2014 | 53,872.00 |
| Mar 31, 2014 | 734,840.00 |
| Mar 31, 2014 | 734,840.00 |
| Sep 30, 2012 | 4,900.00 |
| Sep 30, 2012 | 4,900.00 |
| Jun 30, 2012 | 3,250.00 |
| Jun 30, 2012 | 3,250.00 |